AU2019232768B2 - Treatment of tumors by a combination of an oncolytic adenovirus and a CDK4/6 inhibitor - Google Patents
Treatment of tumors by a combination of an oncolytic adenovirus and a CDK4/6 inhibitorInfo
- Publication number
- AU2019232768B2 AU2019232768B2 AU2019232768A AU2019232768A AU2019232768B2 AU 2019232768 B2 AU2019232768 B2 AU 2019232768B2 AU 2019232768 A AU2019232768 A AU 2019232768A AU 2019232768 A AU2019232768 A AU 2019232768A AU 2019232768 B2 AU2019232768 B2 AU 2019232768B2
- Authority
- AU
- Australia
- Prior art keywords
- inhibitor
- cdk4
- adenovirus
- xvir
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18000210 | 2018-03-05 | ||
| EPEP18000210.7 | 2018-03-05 | ||
| PCT/EP2019/000067 WO2019170283A1 (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019232768A1 AU2019232768A1 (en) | 2020-09-03 |
| AU2019232768B2 true AU2019232768B2 (en) | 2025-12-18 |
Family
ID=61569019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019232768A Active AU2019232768B2 (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a CDK4/6 inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210038661A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3762004B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021517119A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20210031852A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112533620B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019232768B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092907A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3762004T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2965632T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3762004T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE064471T2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007873VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019170283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021044061A1 (en) * | 2019-09-05 | 2021-03-11 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| KR102341347B1 (ko) * | 2019-11-28 | 2021-12-20 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
| EP4578943A4 (en) * | 2022-08-25 | 2026-02-25 | Fujifilm Corp | PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| PL219321B1 (pl) * | 2002-10-15 | 2015-04-30 | Per Sonne Holm | Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny |
| WO2005052143A2 (de) * | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| WO2012022496A2 (en) * | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| US9271988B2 (en) * | 2011-07-01 | 2016-03-01 | Novartis Ag | Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer |
| SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| AU2014272695B2 (en) * | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| RU2670762C2 (ru) * | 2013-12-31 | 2018-10-25 | Хуаньчжу Фарма Ко., Лтд. | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
-
2019
- 2019-03-05 SG SG11202007873VA patent/SG11202007873VA/en unknown
- 2019-03-05 DK DK19710999.4T patent/DK3762004T3/da active
- 2019-03-05 US US16/978,048 patent/US20210038661A1/en active Pending
- 2019-03-05 KR KR1020207025771A patent/KR20210031852A/ko not_active Ceased
- 2019-03-05 JP JP2020546331A patent/JP2021517119A/ja active Pending
- 2019-03-05 CN CN201980016785.2A patent/CN112533620B/zh active Active
- 2019-03-05 EP EP19710999.4A patent/EP3762004B1/en active Active
- 2019-03-05 KR KR1020267017074A patent/KR20260089640A/ko active Pending
- 2019-03-05 WO PCT/EP2019/000067 patent/WO2019170283A1/en not_active Ceased
- 2019-03-05 HU HUE19710999A patent/HUE064471T2/hu unknown
- 2019-03-05 CA CA3092907A patent/CA3092907A1/en active Pending
- 2019-03-05 ES ES19710999T patent/ES2965632T3/es active Active
- 2019-03-05 AU AU2019232768A patent/AU2019232768B2/en active Active
- 2019-03-05 FI FIEP19710999.4T patent/FI3762004T3/fi active
-
2024
- 2024-10-23 JP JP2024186627A patent/JP2025013934A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| Kobayashi, Susumu, et al. "P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation." Clinical cancer research 5.12 (1999): 4182-4185. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019170283A8 (en) | 2019-11-07 |
| CA3092907A1 (en) | 2019-09-12 |
| CN112533620A (zh) | 2021-03-19 |
| HUE064471T2 (hu) | 2024-03-28 |
| EP3762004B1 (en) | 2023-09-13 |
| EP3762004A1 (en) | 2021-01-13 |
| DK3762004T3 (da) | 2023-11-27 |
| AU2019232768A1 (en) | 2020-09-03 |
| CN112533620B (zh) | 2025-03-28 |
| US20210038661A1 (en) | 2021-02-11 |
| SG11202007873VA (en) | 2020-09-29 |
| ES2965632T3 (es) | 2024-04-16 |
| KR20260089640A (ko) | 2026-06-15 |
| RU2020132466A (ru) | 2022-04-05 |
| JP2025013934A (ja) | 2025-01-28 |
| KR20210031852A (ko) | 2021-03-23 |
| RU2020132466A3 (cg-RX-API-DMAC7.html) | 2022-04-05 |
| WO2019170283A1 (en) | 2019-09-12 |
| FI3762004T3 (fi) | 2023-12-11 |
| JP2021517119A (ja) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5618896B2 (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| US20160074447A1 (en) | Novel use of adenoviruses and nucleic acids that code for said viruses | |
| Alonso et al. | ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo | |
| JP2025013934A (ja) | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 | |
| US10731136B2 (en) | Use of adenovirus and nucleic acids coding therefor | |
| Dias et al. | Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1 | |
| Schipper et al. | Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus | |
| EP1830864A2 (de) | E1 -minus adenoviren und deren verwendung | |
| WO2012022496A2 (en) | Method for killing tumor stem cells | |
| Tookman et al. | RAD51 and BRCA2 enhance oncolytic adenovirus type 5 activity in ovarian cancer | |
| Aguirre-Hernández et al. | Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy | |
| Doloff et al. | Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions | |
| JP7834342B2 (ja) | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 | |
| RU2811278C2 (ru) | Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6 | |
| RU2835886C1 (ru) | Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента | |
| Wang et al. | HSF1 overexpression enhances oncolytic effect of replicative adenovirus | |
| CN102250904B (zh) | 一种预防和/或治疗黑色素瘤的药物 | |
| Guo et al. | Antiglioma effects of combined use of a baculovirual vector expressing wild‐type p53 and sodium butyrate | |
| Liu et al. | Tumor‐Specific Cytolysis Caused by an E1B55K‐Attenuated Adenovirus in Nasopharyngeal Carcinoma is Augmented by Cisplatin | |
| Zhang | TALEN-mediated site-specific integration of human CFTR gene by a helper-dependent adenoviral vector | |
| Aguirre | The oncolytic adenoviral AdΔΔ mutant sensitizes prostate cancer cells to mitoxantrone by promoting apoptosis and attenuating autophagy | |
| Wang et al. | Research HSF1 overexpression enhances oncolytic effect of replicative adenovirus | |
| Thoma | Improving intraperitoneal adenovirus virotherapy for ovarian cancer | |
| CN101538556A (zh) | 腺病毒选择性互补复制的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |